Pharma companies await clarity, eye a dose of stability in India-US deal
With the US accounting for nearly 35% of India’s overall pharma shipments of over $30 billion in FY24-25, the move is expected to bolster growth prospects and pipeline visibility. A potential India-US trade deal offers long-awaited stability for the domestic pharma sector, which plays a critical role in supplying affordable medicines to the US, industry experts told TOI.
With the US accounting for nearly 35% of India’s overall pharma shipments of over $30 billion in FY24-25, the move is expected to bolster growth prospects and pipeline visibility. A potential India-US trade deal offers long-awaited stability for the domestic pharma sector, which plays a critical role in supplying affordable medicines to the US, industry experts told TOI.
